Scientific Publications

Phase 2

• Immunogenicity and Safety of an 18-Month Booster Dose of the VLA15 Lyme Borreliosis Vaccine Candidate After Primary Immunization in Healthy Children, Adolescents, and Adults: A Phase 2, Randomized Controlled Trial
  published 7 November 2025 by Laura Wagner et al.
• Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a      randomised, observer-blind, placebo-controlled, phase 2 trial
  published 25 April 2025 by Laura Wagner MSc et al.
• Lyme borreliosis vaccine VLA15 tested safe and immunogenic in children and adolescents
  published on 25 April 2025 by O. Hajdusek

• Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial
  published 16 July 2024 by Santosh Kumar Ghadge, PhD et al.

• Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
  published 31 May 2024 by Nicole Bézay, PhD et al.
  

Phase 1

• Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults
  published on 4 July 2023 by Nicole Bézay et al.

• A Phase 1 study assessing the safety, immunogenicity and dose-response of VLA15, a multivalent recombinant OspA-based vaccine candidate against Lyme borreliosis, in healthy adults aged below 40 years
  published on 27 October 2019 by Nicole Bézay, PhD et al.

Pre-Clinical

• Preclinical Evidence for the Protective Capacity of Antibodies Induced by Lyme Vaccine Candidate VLA15 in People
  published 17 August 2024 by R. Simon et al.
• Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment
  published on 23 March 2020 by A. Nayak et al.

• The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
  published on 1 September 2017 by Comstedt P. et al.

• Characterization and optimization of a novel vaccine for protection against Lyme borreliosis.
  published on 4 November 2015 by Comstedt P. et al.

• Complete genome sequence of Borrelia afzelii K78 and comparative genome analysis.
  published on 23 March 2015 by Schüler W. et al.

• Design and development of a novel vaccine for protection against Lyme borreliosis
  published on 19 November 2014 by Comstedt P. et al.

• Comparative membrane proteome analysis of three Borrelia species
  published on 1 March 2012 by Gesslbauer B. et al.

Epidemiology, Risk and Disease Burden

• Risk Factors for Lyme Disease in the General Population—A Survey of Adults and Caregivers in 28 States
  published on 21 October 2025 by LH Gould et al.
• Variables for habitat and vertebrate hosts of Ixodes scapularis are the best ecological predictors of the spatial spread of Lyme disease in the United States (2010–2019)
  published on 14 October 2025 by P. Kelly et al.
• Lyme Borreliosis and Tick Surveillance Epidemiology in the WHO Regions of the Americas, Eastern Mediterranean, Europe, South-East Asia, and Western Pacific: A Systematic Literature Review (2005–2022) Beyond North America (Canada, United States of America), European Union Countries, and China
  published on 11 August 2025 by L. Burn et al
  
• Differences in Lyme Disease Diagnosis among Medicaid and Medicare Beneficiaries, United States, 2016–2021
  published on 9 September 2025 by L.H. Gould et al.
• Estimation of medically-attended LB incidence in Norway, Finland and Poland using data from national surveillance and published literature
  published on 14 February 2025 by G. Brestricht et al.
• Prevalence of Borrelia burgdorferi sensu lato infection in the Czech Republic
  published on 30 December 2024 by R. Chlibek et al.
• Lyme borreliosis awareness and risk perception: a survey in 20 European countries
  published on 21 December 2024 by L.H. Gould et al.
• Lyme neuroborreliosis in Japan: Borrelia burgdorferi sensu lato as a cause of meningitis of previously undetermined etiology in hospitalized patients outside of the island of Hokkaido, 2010–2021
  published on 6 December 2024 by M. Ohira et al.
• Incidence of symptomatic Lyme borreliosis in nine European countries
  published in December 2024 by F. Angulo et al.
• Historical Summary of Tick and Animal Surveillance Studies for Lyme Disease in Canada, 1975–2023: A Scoping Review
  published on 29 October 2024 by A. Davison et al.
• Risk factors for Lyme disease among residents of rural, suburban, and urban areas in the United States: a case-control study
  published on 20 September 2024 by L.H. Gould et al.
• Estimated incidence of symptomatic Lyme borreliosis cases in five southern coastal counties in Norway 2022
  published on 18 September 2024 by E. Colby et al.
• Incidence of symptomatic Borrelia burgdorferi sensu lato infection in Romania, 2018−2023
  published on 5 September 2024 by F. Angulo et al.
• Excess Healthcare Costs and Resource Utilisation of Lyme Borreliosis in Germany: A Propensity Score–Matched Cohort Study
  published on 23 August 2024 by G. Brestricht et al.
• Borrelia burgdorferi sensu lato prevalence in Ixodes scapularis from Canada: A thirty-year summary and meta-analysis (1990-2020)
  published on 22 May 2024 by P.H. Kelly et al.
• The Incidence of Lyme Borreliosis Among Children
  published on 3 July 2023 by M. Shafquat et al.

Phase 3

• Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine
  published on October 14, 2024 by Gabriele Maurer, PhD et al.

• Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents
  published on September 4, 2024 by Vera Bürger MSc et al.

• Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
  published on August 12, 2024 by Robert McMahon, PhD et al.

• Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
  published on June 12, 2023 by Martina Schneider et al.

• Progress of Clinical Development of a Live-Attenuated Single Shot Chikungunya Vaccine Candidate – Poster Presented at ECCMID 2022
  published on April 25, 2022 by Robert McMahon et al.

• Chikungunya: Safety up to Day 29 of Phase 3 Clinical Development of a Single-Shot Live-Attenuated Vaccine
  published on November 18, 2021 by Martina Schneider et al.

Phase 1

• Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial
  published on June 1, 2020 by Nina Wressnigg et al.

Pre-Clinical

• Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus
  published on March 23, 2017 by Roques P. et al.

Phase 4

• Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
  published on June 19, 2019 by JP Cramer et al.

• Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.
  published on May 1, 2019 by Taucher et al.

• Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose
  published on September 1, 2018 by Kadlecek et al.

• Japanese encephalitis: the vectors, ecology and potential for expansion.
  published on May 1, 2018 by Pearce et al.

• Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.
  published on March 1, 2018 by Jelinek et al.

• Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
  published on September 1, 2017 by Dubischar et al.

Phase 3

• Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.
  published on September 1, 2017 by Dubischar et al.

• Influence of elemental impurities in aluminum hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, IXIARO®.published on November 4, 2015 by R. Schlegl et al.

• Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).published on November 3, 2011 by E. Schuller et al.

• Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.
  published on March 21, 2011 by S. Eder et al.

• Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up.
  published on September 7, 2020 by Dubischar-Kastner et al.

• Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.
  published on July 19, 2020 by Dubischar-Kastner et al.

• Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.
  published on January 8, 2020 by A. Kaltenböck et al.

• Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.
  published on July 16, 2009 by A.Kaltenböck et al.

• IC51 Japanese encephalitis vaccine.
  published on July 1, 2009 by Kollaritsch et al.

• Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.
  published on March 26, 2009 by E. Schuller et al.

• Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.
  published on November 11, 2008 by E. Schuller et al.

• Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
  published on August 2008 by E. Tauber et al.

• Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study
  published on August 12, 2008 by E. Schuller at al.

• Japanese encephalitis vaccines–needs, flaws and achievements.
  published on May 1, 2008 by E. Tauber et al.

• Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
  published on December 1, 2007 by E. Tauber et al.

• Asian travel: from the rare to the difficult.
  published on May 1, 2018 by G. Learoyd

• Cholera: under diagnosis and differentiation from other diarrhoeal diseases
  published on May 1, 2018 by G. Learoyd